

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 March 2023 (02.03.2023)



(10) International Publication Number
WO 2023/028008 A2

- (51) International Patent Classification:
A61K 38/095 (2019.01)
- (21) International Application Number:
PCT/US2022/041095
- (22) International Filing Date:
22 August 2022 (22.08.2022)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/236,090 23 August 2021 (23.08.2021) US
63/332,994 20 April 2022 (20.04.2022) US
- (71) Applicant: **RIVER 2 RENAL CORP.** [US/US]; c/o Nar-
row River Management, LP, One Rockefeller Plaza, Suite
1204, New York, New York 10020 (US).
- (72) Inventor; and
(71) Applicant: **MAGNI, Guido** [CH/CH]; St Alban Vorstadt
37, 4052 Basel (CH).
- (74) Agent: **ZHANG, Clark** et al.; Goodwin Procter LLP,
100 Northern Avenue, IP DOCKETING DEPT./7TH FL.,
Boston, Massachusetts 02210 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS




FIG. 4

(57) Abstract: The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginine vasopressin (AVP), antidiuretic hormone (ADH), and agripresin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
-